Literature DB >> 8995671

The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

J D Reeves1, T F Schulz.   

Abstract

Several human immunodeficiency virus type 2 (HIV-2) strains have been shown to infect some CD4-negative cell lines (P. R. Clapham, A. McKnight, and R. A. Weiss, J. Virol. 66:3531-3537, 1992). Using molecular clones of HIV-2 with a CD4-independent tropism, we have identified critical amino acid residues in the envelope protein which are required for CD4-independent infection. Mutations located immediately upstream of a proposed coiled coil domain in the transmembrane protein (A526T or I528M) and flanking the base of the V4 loop (L378F and K403R) are crucial for the CD4-independent phenotype. Of several mutations conferring a positive charge in V1, V2, and V3, only the change in V3 (Q310K) helped to enhance the CD4-independent phenotype but could not mediate it on its own. These mutations reduce the amount of soluble CD4 required to trigger CD4-independent cell-cell fusion, suggesting that they lower the activation threshold for the fusion process. After binding to cell surface-anchored CD4, a CD4-independent recombinant envelope protein showed an increased binding of anti-envelope protein antibodies, suggesting either an enhanced binding to cell surfaces or more extensive conformational changes in CD4-independent compared to CD4-dependent envelope proteins. The reduced activation threshold of CD4-independent envelope proteins may thus enable them to utilize a membrane molecule for entry which is not as efficient as CD4 in triggering the conformational changes required for the membrane fusion process. CD4-independent HIV-2 variants may be conceptually similar to influenza virus variants capable of fusing at a higher than normal pH (R. S. Daniels, J. C. Downie, J. A. Hay, M. Knossow, J. J. Skehel, M. L. Wang, and D. C. Wiley, Cell 40:431-439, 1985).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995671      PMCID: PMC191202     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

3.  Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV.

Authors:  S Dewhurst; K Sakai; J Bresser; M Stevenson; M J Evinger-Hodges; D J Volsky
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Fusion mutants of the influenza virus hemagglutinin glycoprotein.

Authors:  R S Daniels; J C Downie; A J Hay; M Knossow; J J Skehel; M L Wang; D C Wiley
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

5.  Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens.

Authors:  H L Ploegh; L E Cannon; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

6.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

8.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus).

Authors:  M A Rey; B Spire; D Dormont; F Barre-Sinoussi; L Montagnier; J C Chermann
Journal:  Biochem Biophys Res Commun       Date:  1984-05-31       Impact factor: 3.575

10.  Infection of brain-derived cells with the human immunodeficiency virus.

Authors:  F Chiodi; S Fuerstenberg; M Gidlund; B Asjö; E M Fenyö
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

View more
  35 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

3.  Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells.

Authors:  H Kaneko; L P Neoh; N Takeda; H Akimoto; T Hishikawa; H Hashimoto; S Hirose; S Karaki; M Takiguchi; H Nakauchi; Y Kaneko; N Yamamoto; I Sekigawa
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.

Authors:  R Bron; P J Klasse; D Wilkinson; P R Clapham; A Pelchen-Matthews; C Power; T N Wells; J Kim; S C Peiper; J A Hoxie; M Marsh
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.

Authors:  Levon G Abrahamyan; Samvel R Mkrtchyan; James Binley; Min Lu; Grigory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway.

Authors:  A Bonavia; B T Bullock; K M Gisselman; B J Margulies; J E Clements
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

9.  A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Authors:  Q Shi; A T Nguyen; Y Angell; D Deng; C-R Na; K Burgess; D D Roberts; F C Brunicardi; N S Templeton
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

10.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.